Efficacy and safety of the use of rebamipide in the scheme of triple eradication therapy of Helicobacter pylori infection: a prospective randomized comparative study
- Authors: Andreev DN1, Maev IV1, Dicheva DT1, Samsonov AA1, Partzvania-Vinogradova EV1
-
Affiliations:
- A.I. Evdokimov Moscow State Medicine and Dentistry, University of the Ministry of Health of Russia
- Issue: Vol 90, No 8 (2018)
- Pages: 27-32
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/32773
- DOI: https://doi.org/10.26442/terarkh201890827-32
- ID: 32773
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
D N Andreev
A.I. Evdokimov Moscow State Medicine and Dentistry, University of the Ministry of Health of Russia
Email: dna-mit8@mail.ru
к.м.н., ассистент каф. пропедевтики внутренних болезней и гастроэнтерологии, н.с. лаб. функциональных методов исследования в гастроэнтерологии Москва, Россия
I V Maev
A.I. Evdokimov Moscow State Medicine and Dentistry, University of the Ministry of Health of Russiaд.м.н., проф., акад. РАН, зав. каф. пропедевтики внутренних болезней и гастроэнтерологии Москва, Россия
D T Dicheva
A.I. Evdokimov Moscow State Medicine and Dentistry, University of the Ministry of Health of Russiaк.м.н., доц. каф. пропедевтики внутренних болезней и гастроэнтерологии Москва, Россия
A A Samsonov
A.I. Evdokimov Moscow State Medicine and Dentistry, University of the Ministry of Health of Russiaд.м.н., проф. каф. пропедевтики внутренних болезней и гастроэнтерологии Москва, Россия
E V Partzvania-Vinogradova
A.I. Evdokimov Moscow State Medicine and Dentistry, University of the Ministry of Health of Russiaаспирант каф. пропедевтики внутренних болезней и гастроэнтерологии Москва, Россия
References
- Маев И.В., Самсонов А.А., Андреев Д.Н. Инфекция Helicobacter pylori. Москва: ГЭОТАР-Медиа; 2016.
- Morgan D.R, Crowe S.E. Helicobacter pylori infection. In: Feldman M, Friedman L.S, Brandt L.J, eds. Sleisenger and Fordtran’s Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. 10th ed. Elsevier; 2015. doi: 616.3.3_dc23
- Hooi J.K.Y, Lai W.Y, Ng W.K, Suen M.M.Y, Underwood F.E, Tanyingoh D, Malfertheiner P, Graham D.Y, Wong V.W.S, Wu J.C.Y, Chan F.K.L, Sung J.J.Y, Kaplan G.G, Ng S.C. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology. 2017;153(2):420-429. doi: 10.1053/j.gastro.2017.04.022
- Маев И.В., Самсонов А.А., Андреев Д.Н., Гречушников В.Б., Коровина Т.И. Клиническое значение инфекции Helicobacter pylori. Клиническая медицина. 2013;91(8):4-12.
- Lanas A, Chan F.K. Peptic ulcer disease. Lancet. 2017;390(10094):613-624. doi: 10.1016/S0140-6736(16)32404-7
- Bauer B, Meyer T.F. The Human Gastric Pathogen Helicobacter pylori and Its Association with Gastric Cancer and Ulcer Disease. Ulcers. 2011;2011:Article ID 340157. doi: 10.1155/2011/340157
- Hansel S.L. Peptic Ulcer Disease. In.: Mayo Clinic Gastroenterology and Hepatology Board Review. NY; 2015. doi: 616.330076_dc23
- Chan F.K, Lau J.Y. Peptic Ulcer Disease. In: Feldman M, Friedman L.S, Brandt L.J, eds. Sleisenger and Fordtran’s Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. 10th ed. Elsevier; 2015.
- Malfertheiner P, Megraud F, O’Morain C.A, Gisbert J.P, Kuipers E.J, Axon A.T, Bazzoli F, Gasbarrini A, Atherton J, Graham D.Y, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar E.M. Management of Helicobacter pylori infection - the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6-30. doi: 10. 1136/gutjnl-2016-312288
- Fallone C.A, Chiba N, van Zanten S.V, Fischbach L, Gisbert J.P, Hunt R.H, Jones N.L, Render C, Leontiadis G.I, Moayyedi P, Marshall J.K. The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. Gastroenterology. 2016;151(1):51-69. doi: 10.1053/j.gastro. 2016.04.006
- Chey W.D, Leontiadis G.I, Howden C.W, Moss S.F. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2017;112(2):212-239. doi: 10.1038/ajg.2016.563
- Маев И.В., Кучерявый Ю.А., Андреев Д.Н., Баркалова Е.В. Эрадикационная терапия инфекции Helicobacter pylori: обзор мировых тенденций. Терапевтический архив. 2014;86(3):94-9.
- Андреев Д.Н., Дичева Д.Т., Маев И.В. Возможности оптимизации эрадикационной терапии инфекции Helicobacter pylori в современной клинической практике. Терапевтический архив. 2017;89(2):84-90. doi: 10.17116/terarkh201789284-90
- Lee J.Y, Park K.S. Optimal First-Line Treatment for Helicobacter pylori Infection: Recent Strategies. Gastroenterol Res Pract. 2016;2016:9086581. doi: 10.1155/2016/9086581
- Казюлин А.Н. Использование ребамипида в качестве гастропротективного и противовоспалительного препарата при лечении язвенной болезни, ассоциированной с инфекцией Helicobacter pylori. Лечебное дело. 2016;(2):51-57.
- Naito Y, Yoshikawa T. Rebamipide: a gastrointestinal protective drug with pleiotropic activities. Expert Rev Gastroenterol Hepatol. 2010 Jun;4(3):261-270. doi: 10.1586/egh.10.25
- Андреев Д.Н., Дичева Д.Т., Парцваниа-Виноградова Е.В. Использование ребамипида в рамках комплексной терапии Helicobacter pylori - ассоциированной язвенной болезни желудка и двенадцатиперстной кишки: систематизация данных литературы. Эффективная фармакотерапия. 2017;16:34-36.
- Iinuma S, Naito Y, Yoshikawa T, Takahashi S, Takemura T, Yoshida N, Kondo M. In vitro studies indicating antioxidative properties of rebamipide. Dig Dis Sci. 1998 Sep;43(9 Suppl):35S-39S. PMID: 9753224
- Yoshida N, Yoshikawa T, Iinuma S, Arai M, Takenaka S, Sakamoto K, Miyajima T, Nakamura Y, Yagi N, Naito Y, Mukai F, Kondo M. Rebamipide protects against activation of neutrophils by Helicobacter pylori. Dig Dis Sci. 1996;41(6):1139-1144. doi: 10.1007/BF02088229
- Hayashi S, Sugiyama T, Amano K, Isogai H, Isogai E, Aihara M, Kikuchi M, Asaka M, Yokota K, Oguma K, Fujii N, Hirai Y. Effect of rebamipide, a novel antiulcer agent, on Helicobacter pylori adhesion to gastric epithelial cells. Antimicrob Agents Chemother. 1998 Aug; 42(8):1895-1899. PMID: 9687380
- Suzuki M, Miura S, Mori M, Kai A, Suzuki H, Fukumura D, Suematsu M, Tsuchiya M. Rebamipide, a novel antiulcer agent, attenuates Helicobacter pylori induced gastric mucosal cell injury associated with neutrophil derived oxidants. Gut. 1994 Oct;35(10):1375-1378. doi: 10.1136/gut.35.10.1375
- Nishizawa T, Nishizawa Y, Yahagi N, Kanai T, Takahashi M, Suzuki H. Effect of supplementation with rebamipide for Helicobacter pylori eradication therapy: a systematic review and meta - analysis. J Gastroenterol Hepatol. 2014;29 Suppl 4:20-24. doi: 10.1111/jgh.12769
- Uotani T, Miftahussurur M, Yamaoka Y. Effect of bacterial and host factors on Helicobacter pylori eradication therapy. Expert Opin Ther Targets. 2015;19(12):1637-1650. doi: 10.1517/14728222.2015.1073261
- Маев И.В., Андреев Д.Н. Молекулярно - генетические предикторы резистентности к антихеликобактерной терапии.Терапевтический архив. 2017;89(8):5-12. doi: 10.17116/terarkh20178985-12
- Li M, Li T, Guo S, Liang H, Jiang D. The effect of MDR1 C3435T polymorphism on the eradication rate of H. pylori infection in PPI-based triple therapy: A meta - analysis. Medicine (Baltimore). 2017;96(13): e6489. doi: 10.1097/MD.0000000000006489
- De Boer W.A, Thys J.C, Borody T.J, Graham D.Y, O’Morain C, Tytgat G.N. Proposal for use of a standard side effect scoring system in studies exploring Helicobacter pylori treatment regimens. Eur J Gastroenterol Hepatol. 1996;8(7):641-643. PMID: 8853251
- Sipponen P, Price A.B. The Sydney system for classification of gastritis 20 years ago. J Gastroenterol Hepatol. 2011;26 Suppl 1:31-34. doi: 10. 1111/j.14401746.2010.06536.x
- Andreev D. Helicobacter pylori Eradication Therapy: Current Regimens. Adv Res Gastroentero Hepatol. 2017;7(2):555710. doi: 10.19080/ARGH.2017.07.555710
- Маев И.В., Андреев Д.Н., Самсонов А.А., Велиев А.М. Современные схемы эрадикационной терапии инфекции Helicobacter pylori: стратегия дифференцированного применения, эффективность и безопасность. Экспериментальная и клиническая гастроэнтерология. 2017;4(140):103-110.
- Terano A, Arakawa T, Sugiyama T, et al. Rebamipide, a gastro - protective and anti - inflammatory drug, promotes gastric ulcer healing following eradication therapy for Helicobacter pylori in a Japanese population: a randomized, double - blind, placebo - controlled trial. J Gastroenterol. 2007;42(8):690-693. doi: 10.1007/s00535-007-2076-2
- Song K.H, Lee Y.C, Fan D.M, et al. Healing effects of rebamipide and omeprazole in Helicobacter pylori - positive gastric ulcer patients after eradication therapy: a randomized double - blind, multinational, multi - institutional comparative study. Digestion. 2011;84(3):221-229. doi: 10.1159/000329353
- Fujioka T, Arakawa T, Shimoyama T, Yoshikawa T, Itoh M, Asaka M, Ishii H, Kuwayama H, Sato R, Kawai S, Takemoto T, Kobayashi K. Effects of rebamipide, a gastro - protective drug on the Helicobacter pylori status and inflammation in the gastric mucosa of patients with gastric ulcer: a randomized double - blind placebo - controlled multicentre trial. Aliment Pharmacol Ther. 2003;18 Suppl 1:146-152. doi: 10. 1046/j.1365-2036.18.s1.20.x
- Kamada T, Sato M, Tokutomi T, Watanabe T, Murao T, Matsumoto H, Manabe N, Ito M, Tanaka S, Inoue K, Shiotani A, Akiyama T, Hata J, Haruma K. Rebamipide improves chronic inflammation in the lesser curvature of the corpus after Helicobacter pylori eradication: a multicenter study. Biomed Res Int. 2015;2015:865146. doi: 10.1155/ 2015/865146